JP2017529859A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529859A5
JP2017529859A5 JP2017517098A JP2017517098A JP2017529859A5 JP 2017529859 A5 JP2017529859 A5 JP 2017529859A5 JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017517098 A JP2017517098 A JP 2017517098A JP 2017529859 A5 JP2017529859 A5 JP 2017529859A5
Authority
JP
Japan
Prior art keywords
single nucleotide
breast cancer
risk
female subject
linkage disequilibrium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017517098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529859A (ja
JP6820838B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050583 external-priority patent/WO2016049694A1/en
Publication of JP2017529859A publication Critical patent/JP2017529859A/ja
Publication of JP2017529859A5 publication Critical patent/JP2017529859A5/ja
Application granted granted Critical
Publication of JP6820838B2 publication Critical patent/JP6820838B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017517098A 2014-09-30 2015-09-29 乳癌発症リスクを評価する方法 Expired - Fee Related JP6820838B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
AU2014903898 2014-09-30
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (3)

Publication Number Publication Date
JP2017529859A JP2017529859A (ja) 2017-10-12
JP2017529859A5 true JP2017529859A5 (enExample) 2018-11-08
JP6820838B2 JP6820838B2 (ja) 2021-01-27

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017517098A Expired - Fee Related JP6820838B2 (ja) 2014-09-30 2015-09-29 乳癌発症リスクを評価する方法

Country Status (11)

Country Link
US (2) US10920279B2 (enExample)
EP (1) EP3201360A4 (enExample)
JP (1) JP6820838B2 (enExample)
KR (1) KR102334702B1 (enExample)
CN (1) CN107002138B (enExample)
AU (2) AU2015327756B2 (enExample)
CA (1) CA2962691C (enExample)
IL (1) IL251376B (enExample)
MX (1) MX392267B (enExample)
SG (1) SG11201702416YA (enExample)
WO (1) WO2016049694A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2458017T3 (en) 2005-11-29 2017-07-03 Cambridge Entpr Ltd Markers for breast cancer
MX2011012913A (es) 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
KR102334702B1 (ko) 2014-09-30 2021-12-06 지네틱 테크놀로지스 리미티드 유방암 발생 위험의 평가 방법
AU2018213400A1 (en) * 2017-01-24 2019-08-22 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
SG11202003184WA (en) * 2017-10-13 2020-05-28 Genetic Tech Limited Methods of assessing risk of developing breast cancer
CN108060229A (zh) * 2017-12-27 2018-05-22 沃森克里克(北京)生物科技有限公司 一种TERT基因rs10069690位点SNP核酸质谱检测方法
CN110628912A (zh) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 检测多态性的引物及方法
KR102169699B1 (ko) * 2019-12-27 2020-10-23 주식회사 클리노믹스 유전자 검사를 위한 맞춤형 유전자칩 및 이의 제작 방법
CA3179313A1 (en) * 2020-05-27 2021-12-02 Gillian Sue Dite Methods of assessing risk of developing a severe response to coronavirus infection
CN112687330A (zh) * 2020-12-29 2021-04-20 北京易奇科技有限公司 一种乳腺癌患者携带胚系致病变异的风险预测系统
CN115762635A (zh) * 2021-12-27 2023-03-07 河北北方学院附属第一医院 基于分子标记的用于肝癌筛查和风险预测的系统及应用
US20250149176A1 (en) * 2023-11-08 2025-05-08 Optum Services (Ireland) Limited Model-based risk prediction and treatment pathway prioritization

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69433180T2 (de) 1993-10-26 2004-06-24 Affymetrix, Inc., Santa Clara Felder von nukleinsaeuresonden auf biologischen chips
EP0912766B2 (en) 1996-06-04 2011-12-14 University of Utah Research Foundation Monitoring hybridization during pcr
ATE199025T1 (de) 1996-11-07 2001-02-15 Oklahoma Med Res Found Test zur diagnose eines erhöhten brustkrebs- risikos
AU3108200A (en) 1998-12-02 2000-06-19 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
WO2002008467A1 (en) 2000-07-25 2002-01-31 Dz Genes Llc DIAGNOSTIC POLYMORPHISMS FOR THE ecNOS PROMOTER
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
AU2002322775A1 (en) 2001-07-27 2003-02-17 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
US20040002071A1 (en) 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
WO2005014846A2 (en) * 2003-07-24 2005-02-17 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
WO2005024067A2 (en) 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
DK2458017T3 (en) 2005-11-29 2017-07-03 Cambridge Entpr Ltd Markers for breast cancer
CA2656199A1 (en) 2006-06-23 2007-12-27 Intergenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
KR20090127939A (ko) * 2007-03-26 2009-12-14 디코드 제네틱스 이에이치에프 유방암의 위험도 평가, 진단, 예후 및 치료용 마커인 염색체 2 및 염색체 16 상의 유전적 변이
KR20100017865A (ko) 2007-05-25 2010-02-16 디코드 제네틱스 이에이치에프 유방암의 위험도 평가, 진단, 예후 및 치료용 마커인 염색체 5p12 및 염색체 10q26 상의 유전적 변이
US20090029375A1 (en) 2007-07-11 2009-01-29 Intergenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
US20100042438A1 (en) 2008-08-08 2010-02-18 Navigenics, Inc. Methods and Systems for Personalized Action Plans
EP2335174A1 (en) 2008-09-12 2011-06-22 Navigenics INC. Methods and systems for incorporating multiple environmental and genetic risk factors
MX2011012913A (es) * 2009-06-01 2012-02-21 Genetic Technologies Ltd Métodos para evaluar el riesgo de cáncer de mama.
AU2010265889A1 (en) * 2009-06-25 2012-01-19 Yale University Single nucleotide polymorphisms in BRCA1 and cancer risk
WO2013151413A1 (en) * 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
KR102334702B1 (ko) 2014-09-30 2021-12-06 지네틱 테크놀로지스 리미티드 유방암 발생 위험의 평가 방법
AU2018213400A1 (en) 2017-01-24 2019-08-22 Genetic Technologies Limited Improved methods for assessing risk of developing breast cancer
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
SG11202003184WA (en) 2017-10-13 2020-05-28 Genetic Tech Limited Methods of assessing risk of developing breast cancer

Similar Documents

Publication Publication Date Title
JP2017529859A5 (enExample)
Fehlmann et al. Evaluating the use of circulating microRNA profiles for lung cancer detection in symptomatic patients
ES2962775T3 (es) Método para predecir el pronóstico de pacientes con cáncer de mama
JP7452894B2 (ja) 遺伝子のcpgメチル化変化を用いた肝癌の予後または危険度を評価する方法
Zhang et al. Comprehensive one-step molecular analyses of mitochondrial genome by massively parallel sequencing
JP2018505658A5 (enExample)
CA2978442A1 (en) Methods for assessing the risk of disease occurrence or recurrence using expression level and sequence variant information
Rodriguez-Reyna et al. HLA class I and II blocks are associated to susceptibility, clinical subtypes and autoantibodies in Mexican systemic sclerosis (SSc) patients
JP6606554B2 (ja) Y染色体のメチル化部位を前立腺ガンの診断用マーカとする使用
CN104178567B (zh) 一种与乳腺癌辅助诊断相关的snp标志物及其应用
CN108323184A (zh) 验证生物标志物测量
JP2019510473A5 (enExample)
CN106591438A (zh) 一种用于检测Her2基因的核酸组合、试剂盒及应用
JP2021502069A5 (enExample)
Scannell Bryan et al. Genome-wide association studies and heritability estimates of body mass index related phenotypes in Bangladeshi adults
CN106148529A (zh) 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用
CN105603101A (zh) 检测8个miRNA表达量的系统在制备诊断或辅助诊断肝细胞癌产品中的应用
TW201741915A (zh) 基因表現圖譜以及將其應用於乳癌醫療之方法
Xin et al. Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma
CN104293919A (zh) 一种与非吸烟女性肺癌辅助诊断相关的snp标志物及其应用
CN103911440B (zh) 一种与铂类化疗药物肝脏毒性相关的snp标志物及其应用
JP5461959B2 (ja) 神経膠腫予後予測方法、およびそれに用いるキット
WO2016066797A2 (en) Ovarian cancer prognostic subgrouping
RU2440415C1 (ru) Набор синтетических олигонуклеотидов для определения нуклеотидной последовательности кодирующей части гена brca1 и выявления мутаций, ассоциированных с наследственными формами рака молочной железы
CN105087758A (zh) 一种肺癌预后预测miRNA检测试剂盒